{
    "id": 15486,
    "fullName": "CTAG1B positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CTAG1B positive indicates the presence of the CTAG1B gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1485,
        "geneSymbol": "CTAG1B",
        "terms": [
            "CTAG1B",
            "CT6.1",
            "CTAG",
            "CTAG1",
            "ESO1",
            "LAGE-2",
            "LAGE2B",
            "NY-ESO-1"
        ]
    },
    "variant": "positive",
    "createDate": "12/20/2015",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16785,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine demonstrated initial antitumor activity at day 30 in 66% (4/6) of patients with CTAG1B (NY-ESO-1)-positive advanced sarcoma, resulted in partial response in 2 of the patients at day 90, with 1 patient eventually reached an ongoing complete response for over 4 years (PMID: 30573690; NCT02070406).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 2696,
                "therapyName": "NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19407,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ID-LV305 treatment induced anti-NY-ESO-1 immune response in 52% (20/38) of patients with CTAG1B (NY-ESO-1)-positive advanced solid tumors, resulted in a disease control rate of 56.4% (22/38, 1 confirmed partial response (PR), 1 unconfirmed PR, 20 stable diasese), a median progression-free survival of 4.6 months, and a median overall survival of 31.1 months (PMID: 31227504; NCT02122861).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 3271,
                "therapyName": "ID-LV305",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16990,
                    "pubMedId": 31227504,
                    "title": "First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227504"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19422,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ID-LV305 treatment induced anti-NY-ESO-1 immune response in patients with CTAG1B (NY-ESO-1)-positive synovial sarcoma, resulted in a disease control rate of 53.8% (7/13, 1 partial response, 6 stable diasese), and a median progression-free survival of 2.8 months (PMID: 31227504; NCT02122861).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 3271,
                "therapyName": "ID-LV305",
                "synonyms": null
            },
            "indication": {
                "id": 5485,
                "name": "synovial sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16990,
                    "pubMedId": 31227504,
                    "title": "First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227504"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19409,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ID-LV305 treatment induced anti-NY-ESO-1 immune response in 57% (20/24) of patients with CTAG1B (NY-ESO-1)-positive sarcoma, resulted in a disease control rate of 62.5% (15/24, 1 partial response, 14 stable diasese), a median progression-free survival of 4.6 months, and a median overall survival of 33.9 months (PMID: 31227504; NCT02122861).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 3271,
                "therapyName": "ID-LV305",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16990,
                    "pubMedId": 31227504,
                    "title": "First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227504"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16788,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine and Yervoy (ipilimumab) demonstrated initial antitumor activity at day 30 in 1 of 2 patients with CTAG1B (NY-ESO-1)-positive synovial sarcoma, but did not result in objective response at day 90 (PMID: 30573690; NCT01697527).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 8197,
                "therapyName": "Ipilimumab + NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 5485,
                "name": "synovial sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19423,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ID-LV305 treatment induced anti-NY-ESO-1 immune response in patients with CTAG1B (NY-ESO-1)-positive myxoid liposarcoma, resulted in a disease control rate of 83.3% (5/6, 6 stable diasese), and a median progression-free survival of 9.6 months (PMID: 31227504; NCT02122861).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 3271,
                "therapyName": "ID-LV305",
                "synonyms": null
            },
            "indication": {
                "id": 5363,
                "name": "myxoid liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16990,
                    "pubMedId": 31227504,
                    "title": "First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227504"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16789,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine and Yervoy (ipilimumab) demonstrated initial antitumor activity at day 30 in 1 of 2 patients with CTAG1B (NY-ESO-1)-positive melanoma, but did not result in objective response at day 90 (PMID: 30573690; NCT01697527).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 8197,
                "therapyName": "Ipilimumab + NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16787,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine demonstrated initial antitumor activity at day 30 in a patient with CTAG1B (NY-ESO-1)-positive osteosarcoma, but the disease progressed at day 90 (PMID: 30573690; NCT02070406).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 2696,
                "therapyName": "NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16786,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine demonstrated initial antitumor activity at day 30 in 3 patients with CTAG1B (NY-ESO-1)-positive synovial sarcoma, resulted in partial response in 2 of the patients at day 90, with 1 patient eventually reached an ongoing complete response for over 4 years (PMID: 30573690; NCT02070406).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 2696,
                "therapyName": "NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 5485,
                "name": "synovial sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15750,
            "profileName": "CTAG1B positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}